2022
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
Ahangari F, Becker C, Foster DG, Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead B, Meador C, Correll K, Lili LN, Roybal HM, Rose KA, Ding S, Barnthaler T, Briones N, DeIuliis G, Schupp JC, Li Q, Omote N, Aschner Y, Sharma L, Kopf KW, Magnusson B, Hicks R, Backmark A, Dela Cruz CS, Rosas I, Cousens LP, Dudley JT, Kaminski N, Downey GP. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1463-1479. PMID: 35998281, PMCID: PMC9757097, DOI: 10.1164/rccm.202010-3832oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisHuman precision-cut lung slicesPrecision-cut lung slicesPulmonary fibrosisNormal human lung fibroblastsEpithelial-mesenchymal transitionHuman lung fibroblastsFibrogenic pathwaysPreclinical modelsMurine modelLung slicesSrc kinase inhibitorLung fibroblastsKinase inhibitorsAmelioration of fibrosisSelective Src kinase inhibitorHuman lung fibrosisWhole lung extractsPotential therapeutic efficacyIPF diseaseIPF treatmentLung functionInflammatory cascadeLung fibrosisAntifibrotic efficacy
2021
FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
Frye B, Potasso L, Farin-Glattacker E, Birring S, Müller-Quernheim J, Schupp J. FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients. BMC Pulmonary Medicine 2021, 21: 395. PMID: 34861850, PMCID: PMC8643005, DOI: 10.1186/s12890-021-01761-7.Peer-Reviewed Original ResearchConceptsKing's Sarcoidosis QuestionnaireBody mass indexSarcoidosis patientsQuality of lifeSerological parametersHigher body mass indexGerman Clinical Trials RegisterLife style modificationClinical Trials RegisterEffect of obesitySteroid-sparing therapiesLung functional parametersGeneral health statusOrgan-specific domainsConclusionThis observationKSQ scoresTrials RegisterClinical chartsMethodsClinical dataOrgan manifestationsLung functionMass indexClinical parametersStyle modificationTRIAL REGISTRATIONAbnormal FeV1 and body mass index are associated with impaired cough-related quality of life in sarcoidosis patients
Frye B, Potasso L, Farin E, Fichtner U, Birring S, Müller-Quernheim J, Schupp J. Abnormal FeV1 and body mass index are associated with impaired cough-related quality of life in sarcoidosis patients. Respiratory Medicine 2021, 188: 106600. PMID: 34530353, DOI: 10.1016/j.rmed.2021.106600.Peer-Reviewed Original ResearchConceptsLeicester Cough QuestionnaireCough-related qualityQuality of lifeSarcoidosis patientsLCQ scoreBody mass indexAbnormal FEV1Routine followLung functionOrgan impairmentTreatable traitsMass indexDisease burdenGranulomatous diseaseFEV1PatientsSarcoidosisBMIScoresQuestionnaireLungCohortFollowDiseaseLife
2020
Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome
Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC, Kaminski N, Jenne D, Eickelberg O, Yildirim AÖ. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. European Respiratory Journal 2020, 57: 2001416. PMID: 33303550, DOI: 10.1183/13993003.01416-2020.Peer-Reviewed Original ResearchConceptsBronchoalveolar lavage fluidCathepsin B activityHealthy donorsLung tissueCollagen depositionB activityCathepsin BBronchiolitis obliterans syndromeProgression of BOSFluorescence resonance energy transfer-based assayPromising therapeutic targetGrowth factor-β1Cathepsin B levelsSubsequent collagen depositionBOS pathogenesisBOS patientsBOS progressionLTx patientsLymphocytic bronchiolitisObliterans syndromeLung transplantationPeribronchial fibrosisPulmonary dysfunctionLung functionMajor complications
2016
Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases
Schupp J, Köhler T, Müller-Quernheim J. Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases. Respiration 2016, 91: 296-301. PMID: 27082957, DOI: 10.1159/000445031.Peer-Reviewed Original ResearchConceptsNon-specific interstitial pneumoniaInterstitial lung diseaseLymphocytic interstitial pneumoniaCyclophosphamide pulse therapyLung functionPulse therapyInterstitial pneumoniaLung diseaseRheumatoid arthritis-associated interstitial lung diseaseIdiopathic non-specific interstitial pneumoniaFibrotic interstitial lung diseaseProgressive lung function declineBetter survival outcomesLung function declineIdiopathic pulmonary fibrosisBronchoalveolar lavage cytologyGroup of disordersILD patientsMost patientsSystemic sclerosisTotal cohortFunction declineLavage cytologyPulmonary fibrosisCyclophosphamide treatment